An observational study in Heart Failure, sponsored by Carolina Ortiz Cortes. Recruiting at 24 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Carolina Ortiz Cortes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 342 studies in Heart Failure with a site in Spain — 76 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Spain.
Among the 342 studies in Heart Failure with a site in Spain, this one is the 45th largest by planned enrollment of the 78 observational ones that give a count, is one of 22 that started in 2026, is one of 78 observational ones, reaches primary completion later than 66 of the 98 other live ones, and was the 342nd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →76 of the 342 studies in Heart Failure with a site in Spain are open now. Recruiting first, the newest first:
AnaCardio AB · Sites in Spain, United States, Bulgaria and 5 more countries
Ages 18–85
AstraZeneca · Sites in Spain, United States, Argentina and 29 more countries
Ages 18+
AstraZeneca · Sites in Spain, United States, Germany and 2 more countries
Ages 18+
Biotronik SE & Co. KG · Sites in Spain, Austria, Czechia and 4 more countries
Ages 18–99
Axon Therapies, Inc. · Sites in Spain, Czechia, Georgia and 2 more countries
Ages 40+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 42 · Phase 3 78 · Phase 4 24
First in 1983; this study’s year is marked. 22 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 430 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 294 across the 263 interventional studies, 500 across the 78 observational. Of the 213 that completed or were terminated, 86 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
190 of 342 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Carolina Ortiz Cortes as lead sponsor.
Carolina Ortiz Cortes has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
31 of the studies in Heart Failure with a site in Spain that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07008365Phase 3Instituto de Investigación Sanitaria AragónThe Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure | 2026-11-30 |
| NCT06578078Phase 3Fundación para la Investigación del Hospital Clínico de ValenciaA Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | 2026-12-30 |
| NCT06712030Phase 3Puerta de Hierro University HospitalEffect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction | 2027-04 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
Add all 31 to your calendar (.ics) → With an account.
Among the 342 studies in Heart Failure with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Heart failure (HF) is a leading cause of hospital admission in older adults and women account for more than half of these admissions, yet they remain under-represented in prospective HF cohorts. Risk factors specific to women, such as complications of pregnancy and the timing of menopause, are seldom recorded in HF registries, and treatment is usually described by drug class rather than by the dose actually achieved.
HER-HF is a national, prospective, multicenter observational cohort study that enrolls women aged 18 years or older admitted to hospital for a first episode of HF, irrespective of left ventricular ejection fraction, at 24 Spanish hospitals with a dedicated heart failure unit. Recruitment is consecutive and all-comers. Participants are enrolled at discharge from the index admission or at the first heart failure unit visit within 15 days, and all baseline data refer to the index hospitalization. Participants are followed for 12 months, with visits at 3, 6 and 12 months.
The primary objective is descriptive: to characterize the epidemiological, clinical, diagnostic, therapeutic and prognostic profile of women with de novo HF, from the index admission through 12 months. Secondary objectives are: (1) to evaluate the association of sex-specific risk factors with the clinical profile, the type of HF (ejection fraction phenotype and etiology), the management received and 12-month prognosis, adjusted for traditional risk factors; (2) to examine the association of individual social determinants (household income, number of people in the household and educational attainment) with the type of HF, age at onset, management and outcome; and (3) to compare the cohort with a contemporary cohort of men with newly diagnosed HF (TIDY-HF registry) to identify sex-specific differences. The principal prognostic endpoint is the composite of all-cause death or HF decompensation (hospitalization for HF, or an unplanned emergency department or day-hospital visit for HF) within 12 months.
Data are collected in a centralized, encrypted electronic case report form. Baseline variables include demographics, cardiovascular risk factors and comorbidity, previous cardiological history and prior medication; sex-specific risk factors recorded in the clinical history of the index admission (number of pregnancies and deliveries; preeclampsia, eclampsia or HELLP syndrome; gestational hypertension and gestational diabetes; preterm delivery; intrauterine growth restriction or small-for-gestational-age newborn; peripartum cardiomyopathy; recurrent pregnancy loss; menopausal status and age at menopause; hormone replacement therapy; polycystic ovary syndrome; and endometriosis); previous cardiotoxic cancer therapy (chemotherapy or radiotherapy), recorded with the oncological history as a female-predominant risk factor; individual social determinants (net monthly household income, number of people in the household and educational attainment); clinical features of the index episode; laboratory, electrocardiographic and echocardiographic data; cardiac magnetic resonance, coronary angiography and other investigations when performed; treatment at discharge by drug class and dose band, with adverse effects and whether these led to dose reduction or withdrawal; devices and cardiac interventions; and the Barthel index, the Pfeiffer questionnaire, the five-item Geriatric Depression Scale and the 12-item Kansas City Cardiomyopathy Questionnaire.
At each follow-up visit (3, 6 and 12 months) the following are recorded: functional class, physical examination for residual congestion, weight and blood pressure, laboratory tests and electrocardiogram, current treatment with doses, tolerability and adverse effects, emergency department attendances and day-hospital treatments for heart failure, hospitalizations for heart failure, for other cardiovascular causes and for non-cardiovascular causes, referral to cardiac rehabilitation and referral for advanced therapies. Echocardiography is performed at the index admission, once during follow-up at the 3- or 6-month visit, and again by the 12-month visit. Vital status and cause of death are recorded throughout; clinical events are ascertained by the site investigator from the clinical and regional electronic health records, without central adjudication. Functional and health-status scales are repeated at 12 months.
To document and control selection bias, each site declares a fixed screening frame in advance and maintains a screening log recording the number of women screened, the number confirmed eligible, the number enrolled, and the number of eligible women not enrolled with the reason. Participation rates will be reported by site.
The sample size was calculated for descriptive precision: with the most conservative proportion (p = 0.50), 95% confidence and an absolute precision of 5%, 385 evaluable women are required; allowing for 10% loss to follow-up over 12 months, 430 women will be recruited. Results will be presented overall and by ejection fraction phenotype according to the 2026 European Society of Cardiology definitions (reduced, below 50%; preserved, 50% or higher; also reporting 40% or lower and 41-49% separately) and by age (under 75 or 75 years and older). Time to the composite endpoint will be analyzed with Kaplan-Meier curves and Cox models with standard errors clustered by center; all secondary analyses are exploratory. The comparison with the men of the TIDY-HF registry will include all women for clinical profile and investigations, and women with an ejection fraction of 40% or lower, the population enrolled in TIDY-HF, for the class and dose of foundational medical therapy, with adjustment for age.
The criteria were revised on the registry on Oct 21, 2026. See what changed
Women aged 18 years or older admitted to hospital with a first episode of heart failure at 24 participating Spanish centers, all of which have a dedicated heart failure unit. Recruitment is consecutive and all-comers: every woman meeting the criteria during the recruitment period is offered participation, and discretionary selection by investigators is not permitted. Each center declares a fixed screening frame in advance and keeps a screening log of women screened, women confirmed eligible, women enrolled, and eligible women not enrolled with the reason. Concurrent participation in an interventional trial is not an exclusion criterion but is recorded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women aged 18 years or older admitted to hospital with a first episode of heart failure confirmed by the treating team according to current clinical practice guidelines, irrespective of left ventricular ejection fraction, and with no previous diagnosis of heart failure. Participants are enrolled consecutively (all-comers) at discharge from the index admission or at the first heart failure unit visit within 15 days of discharge, and are followed for 12 months with visits at 3, 6 and 12 months. No intervention is assigned by the protocol; all diagnostic and therapeutic decisions are made by the treating clinician as part of routine care.
Composite of all-cause death or heart failure decompensation
Time from enrollment to the earlier of death from any cause or heart failure decompensation, defined as hospitalization with heart failure as the principal reason for admission, or an unplanned emergency department or day-hospital visit for worsening heart failure. Events are ascertained by the site investigator from the clinical and regional electronic health records at each scheduled visit; there is no central adjudication.
Time frame: 12 months from enrollment
All-cause mortality
Proportion of participants who die from any cause during follow-up, with date and cause of death recorded and classified as cardiovascular or non-cardiovascular.
Time frame: 12 months from enrollment
Rehospitalization for heart failure
Number of participants with at least one hospital admission with heart failure as the principal reason for admission, and the total number of such admissions.
Time frame: 12 months from enrollment
Prevalence of sex-specific and female-predominant risk factors
Proportion of participants with each recorded sex-specific risk factor: number of pregnancies and deliveries, preeclampsia, eclampsia or HELLP syndrome, gestational hypertension, gestational diabetes, preterm delivery before 37 weeks, intrauterine growth restriction or small-for-gestational-age newborn, peripartum cardiomyopathy, recurrent pregnancy loss, premature menopause before 40 years, hormone replacement therapy, polycystic ovary syndrome and endometriosis; and proportion with previous cardiotoxic cancer therapy (chemotherapy or radiotherapy), recorded as a female-predominant risk factor.
Time frame: Baseline (index hospitalization)
Distribution of left ventricular ejection fraction phenotype
Proportion of participants in each left ventricular ejection fraction category measured by transthoracic echocardiography during the index hospitalization: reduced (below 50%) or preserved (50% or higher) according to the 2026 European Society of Cardiology definitions, also reporting 40% or lower and 41-49% separately.
Time frame: Baseline (index hospitalization)
Use and achieved dose of disease-modifying heart failure therapy
Proportion of participants receiving each class of disease-modifying therapy (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists, finerenone, sodium-glucose cotransporter 2 inhibitors, vericiguat, ivabradine, diuretics and potassium binders) and the dose band achieved for each.
Time frame: Discharge from the index hospitalization and 3, 6 and 12 months
Adverse effects limiting disease-modifying therapy
Proportion of participants with hypotension, bradycardia, conduction disturbance, worsening renal function, hyperkalemia or other adverse effects attributed to disease-modifying therapy, and whether these led to dose reduction or withdrawal of the drug.
Time frame: 12 months from enrollment
Change in the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) overall summary score
Change from baseline in the overall summary score of the 12-item Kansas City Cardiomyopathy Questionnaire. The score ranges from 0 to 100, with higher scores indicating better health status.
Time frame: Baseline and 12 months
Functional and cognitive status scales
Barthel index (0 to 100, higher scores indicate greater independence), Pfeiffer Short Portable Mental Status Questionnaire (0 to 10 errors, higher scores indicate greater cognitive impairment) and the five-item Geriatric Depression Scale (0 to 5, higher scores indicate more depressive symptoms).
Time frame: Baseline and 12 months
Emergency department attendances and day-hospital treatments for heart failure
Number of participants attending the emergency department or receiving intravenous diuretic treatment in a day-hospital setting for worsening heart failure, and the number of such episodes.
Time frame: 12 months from enrollment
Referral to cardiac rehabilitation and to advanced heart failure therapies
Proportion of participants referred to a cardiac rehabilitation program and proportion referred for evaluation for heart transplantation or ventricular assist device.
Time frame: 12 months from enrollment
Hospitalization for cardiovascular causes other than heart failure and for non-cardiovascular causes
Number of participants admitted to hospital for a cardiovascular cause other than heart failure, and number admitted for a non-cardiovascular cause, with the number of such admissions.
Time frame: 12 months from enrollment
Individual social determinants
Distribution of net monthly household income (euros), number of people in the household (including the participant) and educational attainment, recorded in six categories: unable to read or write or incomplete primary education; complete primary education; lower secondary education; upper secondary education or vocational training; university education; unknown or declined to answer. These variables are analyzed as exposures against the type of heart failure, age at onset, management and outcome.
Time frame: Baseline (index hospitalization)
Plan to share: No — Individual participant data will not be made publicly available. Requests for scientific collaboration should be addressed to the coordinating investigator and will be considered by the steering committee of the registry.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Mar 2028, 18 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 18 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.